Landing
Macula Society 2022
Characterizing Real-world Functional Outcomes in Patients With Geographic Atrophy: An IRIS Registry Analysis
Impact of the Complement C3 Inhibitor Pegcetacoplan on Photoreceptor Degeneration beyond Areas of Geographic Atrophy in the FILLY Trial
Geographic Atrophy Lesion Growth in Pegcetacoplan-treated Study Eyes Versus Untreated Fellow Eyes in Patients with Bilateral GA in the OAKS, DERBY, and FILLY Trials
Efficacy of Pegcetacoplan in Subgroups Defined by Distance from the Foveal Center Point in the Phase 3 OAKS and DERBY studies of Patients with Geographic Atrophy
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.